DOV
71
2
MCHP
41
-4
ACN
49
2
PM
54
-2
DE
40
4
KLAC
47
-3
HP
44
3
DGX
48
-2
NWS
79
-4
KSS
46
7
MNST
68
3
EXPD
40
-3
ROP
62
-3
JNPR
54
-2
KMI
83
2
URBN
67
5
CNP
46
-4
HON
70
5
ADSK
75
3
CF
53
5
DOV
71
2
MCHP
41
-4
ACN
49
2
PM
54
-2
DE
40
4
KLAC
47
-3
HP
44
3
DGX
48
-2
NWS
79
-4
KSS
46
7
MNST
68
3
EXPD
40
-3
ROP
62
-3
JNPR
54
-2
KMI
83
2
URBN
67
5
CNP
46
-4
HON
70
5
ADSK
75
3
CF
53
5
Financhill
Back

Soleno Therapeutics 10K Form

Buy
65

SLNO
Soleno Therapeutics

Last Price:
57.36
Seasonality Move:
33.56%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SLNO News And Ratings

See the #1 stock for the next 7 days that we like better than SLNO

SLNO Financial Statistics

Sales & Book Value

Annual Sales: $387.56K
Cash Flow: $-15.12M
Price / Cash Flow: 0
Annual Sales: $6.45
Price / Book: 9.65

Profitability

EPS (TTM): -3.34660
Net Income (TTM): $-131.16M
Gross Margin: $34.87K
Return on Equity: 0%
Return on Assets: 0%

Soleno Therapeutics Earnings Forecast

Key Soleno Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 2 years for SLNO is 9.00%.
  • The Selling, General & Administrative Expenses for SLNO have been equal to 2,032.79% of Gross Profit Margin.
  • The Interest Expense is -3.83% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 9 years.

Soleno Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SLNO
CUSIP: 834203
Website: soleno.life

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SLNO Technical Analysis vs Fundamental Analysis

Buy
65
Soleno Therapeutics (SLNO) is a Buy

Is Soleno Therapeutics a Buy or a Sell?